Targeting RAS–ERK signalling in cancer: promises and challenges
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clinical outcome in metastatic melanoma and has shown promising clinical activity in additional tumour types. However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance. Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently associated with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of single agent therapies targeting individual RAS effector pathways is limited”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“combinations of inhibitors targeting multiple effector and/or feedback pathways have shown impressive activity in KRAS mutant model systems”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“Determinants of primary resistance are not the same in different tumor types that up-regulate various RTKs or their ligands in response to pathway inhibition (111-113).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [113]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Cited by
Items 201–300 of 1,000
Wheeler, E. C., Vora, S., Mayer, D., Kotini, A. G., Olszewska, M., Park, S. S., Guccione, E., Teruya‐Feldstein, J., Silverman, L. R., Sunahara, R. K., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0508 · Cited by 56
Endometrial Carcinoma: Specific Targeted Pathways
Eritja, N., Yeramian, A., Chen, B., Llobet‐Navàs, D., Ortega, E., Colás, E., Abal, M., Dolcet, X., Reventós, J., & Matías‐Guiu, X. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43139-0_6 · Cited by 64
Total Chemical Synthesis and Folding of All- l and All- d Variants of Oncogenic KRas(G12V)
Levinson, A. M., McGee, J. H., Roberts, A. G., Creech, G. S., Wang, T., Peterson, M. T., Hendrickson, R. C., Verdine, G. L., & Danishefsky, S. J. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b02988 · Cited by 59
Rolver, M. G., Elingaard-Larsen, L. O., Andersen, A. P., Counillon, L., & Pedersen, S. F. (2020) · Scientific Reports · doi:10.1038/s41598-020-62430-z · Cited by 59
van Geel, R. M. J. M., van Brummelen, E. M. J., Eskens, F. A. L. M., Huijberts, S. C. F. A., de Vos, F. Y. F. L., Lolkema, M. P. J. K., Devriese, L. A., Opdam, F. L., Marchetti, S., Steeghs, N., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0776-z · Cited by 55
Dabrafenib and its use in the Treatment of Metastatic Melanoma
Bowyer, S. E., Lee, R. J., Fusi, A., & Lorigan, P. C. (2015) · Melanoma Management · doi:10.2217/mmt.15.21 · Cited by 60
A Comprehensive Review of Ovarian Serous Carcinoma
Hatano, Y., Hatano, K., Tamada, M., Morishige, K.-I., Tomita, H., Yanai, H., & Hara, A. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000243 · Cited by 66
Qin, Y., Hu, Q., Ji, S., Xu, J., Dai, W., Liu, W., Xu, W., Sun, Q., Zhang, Z., Ni, Q., et al. (2019) · Cell Proliferation · doi:10.1111/cpr.12603 · Cited by 55
TGFβ as a therapeutic target in cystic fibrosis
Kramer, E. L., & Clancy, J. P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1406922 · Cited by 60
Ding, C., Tang, W., Fan, X., Wang, X., Wu, H., Xu, H., Xu, W., Gao, W., & Wu, G. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0817-1 · Cited by 53
Dual effects of active ERK in cancer: A potential target for enhancing radiosensitivity (Review)
Lu, Y., Liu, B., Liu, Y., Yu, X., & Cheng, G. (2020) · Oncology Letters · doi:10.3892/ol.2020.11684 · Cited by 59
Designed covalent allosteric modulators: an emerging paradigm in drug discovery
Lu, S., & Zhang, J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.013 · Cited by 55
Selt, F., Buhl, J. L., Hielscher, T., Sahm, F., Capper, D., Korshunov, A., Usta, D., Brabetz, S., Ridinger, J., Ecker, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14004 · Cited by 58
Translational control of ERK signaling through miRNA/4EHP-directed silencing
Jafarnejad, S. M., Chapat, C., Matta-Camacho, E., Gelbart, I. A., Hesketh, G. G., Arguello, M., Garzia, A., Kim, S.-H., Attig, J., Shapiro, M., et al. (2018) · eLife · doi:10.7554/elife.35034 · Cited by 53
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
Boga, S. B., Deng, Y., Zhu, L., Nan, Y., Cooper, A. B., Shipps, G. W., Doll, R., Shih, N.-Y., Zhu, H., Sun, R., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00220 · Cited by 52
Self-citationYounis, N. S., Ghanim, A. M. H., & Saber, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-55666-x · Cited by 53
Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
González‐Hormazábal, P., Musleh, M., Bustamante, M., M, J. S., Pisano, R. V., Héctor Valladares, H., Enrique Lanzarini, S., Chiong, H., Rojas, J., Suazo, J., et al. (2018) · Genes · doi:10.3390/genes10010020 · Cited by 53
The tumor microbiome in cancer progression: mechanisms and therapeutic potential
Zhang, W., Xiang, Y., Ren, H., Liu, Y., Wang, Q., Ran, M., Zhou, W., Lu, T., Zheng, X., Qiao, C., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02403-w · Cited by 64
Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?
Cristea, S., & Sage, J. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.018 · Cited by 55
Zhao, S., Jiang, Y., Zhao, J., Li, H., Yin, X., Wang, Y., Xie, Y., Chen, X., Lü, J., Dong, Z., et al. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22876 · Cited by 58
MiR-182 promotes cell proliferation by suppressing FBXW7 and FBXW11 in non-small cell lung cancer.
Chang, H., Liu, Y., Wang, L., Wang, J., Zhao, Z., Qu, J., & Sheng-fa, W. (2018) · Europe PMC (PubMed Central) · Cited by 51
GINS2 promotes EMT in pancreatic cancer via specifically stimulating ERK/MAPK signaling
Huang, L., Chen, S., Fan, H., Ji, D., Chen, C., & Sheng, W. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0206-7 · Cited by 52
Frontzek, F., Staiger, A. M., Zapukhlyak, M., Xu, W., Bonzheim, I., Borgmann, V., Sander, P., Baptista, M. J., Heming, J.-N., Berning, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25405-w · Cited by 54
Chong, X., Chen, J., Zheng, N., Zhou, Z., Hai, Y., Chen, S., Zhang, Y., Yu, Q., Yu, S., Chen, Z., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01531-x · Cited by 50
Avery, T. Y., Köhler, N., Zeiser, R., Brummer, T., & Ruess, D. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931774 · Cited by 54
Deng, Y., Gao, M., Lu, D., Liu, Q., Zhang, R., Ye, J., Zhao, J., Feng, Z., Li, Q., & Zhang, H. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155169 · Cited by 53
Ye, W.-L., Huang, L., Yang, X., Wan, S., Gan, W.-J., Yang, Y., He, X., Liu, F., Guo, X., Liu, Y.-X., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2406936121 · Cited by 54
The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior
Weinberg, F., Reischmann, N., Fauth, L., Taromi, S., Mastroianni, J., Köhler, M., Halbach, S., Becker, A. C., Deng, N., Schmitz, T., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.015 · Cited by 54
Su, Y., Li, X., Ma, J., Zhao, J., Liu, S., Wang, G., Edwards, H. J., Taub, J. W., Lin, H., & Ge, Y. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.11.022 · Cited by 54
Redox regulation of microRNAs in cancer
Lan, J., Huang, Z., Han, J., Shao, J., & Huang, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.010 · Cited by 50
Vena, F., Jia, R., Esfandiari, A., García-Gómez, J. J., Rodriguez‐Justo, M., Ma, J., Syed, S., Crowley, L., Elenbaas, B., Goodstal, S. M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24294 · Cited by 50
SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics
Boned del Río, I., Young, L. C., Sari, S., Jones, G. G., Ringham-Terry, B., Hartig, N., Rejnowicz, E., Lei, W., Bhamra, A., Surinova, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902658116 · Cited by 50
Mathien, S., Tesnière, C., & Meloche, S. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000170 · Cited by 57
Bridgeman, V. L., Wan, E., Foo, S., Nathan, M. R., Welti, J. C., Frentzas, S., Vermeulen, P., Preece, N., Springer, C. J., Powles, T. B., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0170 · Cited by 52
Li, Y., Li, Y., Ge, P., & Ma, C. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9654-8 · Cited by 49
RetractedHistiocytic neoplasms in the era of personalized genomic medicine
Durham, B. H., Diamond, E. L., & Abdel-Wahab, O. I. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000256 · Cited by 49
Yoon, C., Till, J. E., Cho, S., Chang, K. K., Lin, J.-X., Huang, C., Ryeom, S. W., & Yoon, S. S. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0077 · Cited by 50
RetractedLncRNA LOXL1‐AS1/miR‐28‐5p/SEMA7A axis facilitates pancreatic cancer progression
Liu, Y., Guo, C., Li, F., & Wu, L. (2019) · Cell Biochemistry and Function · doi:10.1002/cbf.3449 · Cited by 50
Selective targeting of point-mutated KRAS through artificial microRNAs
Acunzo, M., Romano, G., Nigita, G., Veneziano, D., Fattore, L., Laganà, A., Zanesi, N., Fadda, P., Fassan, M., Rizzotto, L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620562114 · Cited by 53
Qin, H., Jiang, Y., Zhang, J., Deng, C., & Zhong, Z. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00691 · Cited by 51
Optogenetic actuator – ERK biosensor circuits identify MAPK network nodes that shape ERK dynamics
Dessauges, C., Mikelson, J., Dobrzyński, M., Jacques, M., Frismantiene, A., Gagliardi, P. A., Khammash, M., & Pertz, O. (2022) · Molecular Systems Biology · doi:10.15252/msb.202110670 · Cited by 48
Targeting KRAS mutant lung cancer: light at the end of the tunnel
Drosten, M., & Barbacid, M. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13168 · Cited by 47
Modified gold-based siRNA Nanotherapeutics for Targeted Therapy of triple-negative Breast Cancer
Shahbazi, R., Aşık, E., Kahraman, N., Türk, M., Özpolat, B., & Ulubayram, K. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0081 · Cited by 48
C10orf99 contributes to the development of psoriasis by promoting the proliferation of keratinocytes
Chen, C., Wu, N., Duan, Q., Yang, H., Wang, X., Yang, P., Zhang, M., Liu, J., Liu, Z., Shao, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26996-z · Cited by 52
miR-483-5p decreases the radiosensitivity of nasopharyngeal carcinoma cells by targeting DAPK1
Tian, Y., Yan, M., Zheng, J., Li, R., Lin, J., Xu, A., Liang, Y., Zheng, R., & Yuan, Y. (2019) · Laboratory Investigation · doi:10.1038/s41374-018-0169-6 · Cited by 49
DUSP8 phosphatase: structure, functions, expression regulation and the role in human diseases
Ding, T., Zhou, Y., Long, R., Chen, C., Zhao, J., Cui, P., Guo, M., Liang, G., & Xu, L. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0329-4 · Cited by 52
Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance
Fröhlich, F., Gerosa, L., Muhlich, J. L., & Sorger, P. K. (2023) · Molecular Systems Biology · doi:10.15252/msb.202210988 · Cited by 55
Smorodinsky-Atias, K., Goshen‐Lago, T., Goldberg-Carp, A., Kadosh, D. M., Shir, A., Mooshayef, N., Beenstock, J., Karamansha, Y., Darlyuk‐Saadon, I., Livnah, O., et al. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-07-0521 · Cited by 46
Anti-Cancer Stem-like Cell Compounds in Clinical Development – An Overview and Critical Appraisal
Marcucci, F., Rumio, C., & Lefoulon, F. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00115 · Cited by 51
Wu, J.-Y., Xiang, S., Zhang, M., Fang, B., Huang, H., Kwon, O. K., Zhao, Y., Yang, Z., Bai, W., Bepler, G., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.795955 · Cited by 47
Yao, W., Lin, Z. Y., Wang, G., Li, S., Chen, B., Sui, Y., Huang, J., Liu, Q., Shi, P., Lin, X., et al. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152973 · Cited by 46
Prolyl Isomerase Pin1 in Human Cancer: Function, Mechanism, and Significance
Pu, W., Zheng, Y., & Peng, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00168 · Cited by 52
Yang, S., Tang, Q., Chen, L., Chang, J., Jiang, T., Zhao, J., Wang, M., & Chen, P. R. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202009572 · Cited by 46
PBK promotes aggressive phenotypes of cervical cancer through ERK/c‐Myc signaling pathway
Ma, H., Han, F., Yan, X., Qi, G., Li, Y., Li, R., Yan, S., Yuan, C., Song, K., & Kong, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30134 · Cited by 46
Targeting the RAS upstream and downstream signaling pathway for cancer treatment
Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176727 · Cited by 57
Exogenous Hydrogen Sulfide Regulates the Growth of Human Thyroid Carcinoma Cells
Wu, D., Li, J., Zhang, Q., Tian, W., Zhong, P., Liu, Z., Wang, H., Wang, H., Ji, A., & Li, Y. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6927298 · Cited by 50
Targeting mutated GTPase KRAS in tumor therapies
Fan, G., Lou, L., Song, Z., Zhang, X., & Xiong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113816 · Cited by 48
Metabolite activation of tumorigenic signaling pathways in the tumor microenvironment
Low, V., Li, Z., & Blenis, J. (2022) · Science Signaling · doi:10.1126/scisignal.abj4220 · Cited by 44
Solid tumor therapy by selectively targeting stromal endothelial cells
Liu, S., Liu, J., Ma, Q., Cao, L., Fattah, R. J., Yu, Z., Bugge, T. H., Finkel, T., & Leppla, S. H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600982113 · Cited by 44
Structural basis of autoregulatory scaffolding by apoptosis signal-regulating kinase 1
Weijman, J. F., Kumar, A., Jamieson, S. A., King, C., Caradoc-Davies, T. T., Ledgerwood, E. C., Murphy, J. M., & Mace, P. D. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620813114 · Cited by 45
An automated microfluidic gene-editing platform for deciphering cancer genes
Sinha, H., Quach, A. B. V., Vo, P. Q. N., & Shih, S. C. C. (2018) · Lab on a Chip · doi:10.1039/c8lc00470f · Cited by 46
Role of miR-15a in intervertebral disc degeneration through targeting MAP3K9
Cai, P., Yang, T., Jiang, X., Zheng, M., Xu, G., & Xia, J. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.128 · Cited by 43
Sun, C., Li, C., Li, X., Zhu, Y., Su, Z., Wang, X., He, Q., Zheng, G., & Feng, B. (2018) · Journal of Cancer · doi:10.7150/jca.25921 · Cited by 44
Zhang, B., Zhang, L., Chen, Y., Qiao, X. J., Zhao, S., Li, P., Liu, J., Wen, X., & Yang, J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15372 · Cited by 47
ZEB1: Catalyst of immune escape during tumor metastasis
Lü, J., Fei, F., Wu, C., Mei, J., Xu, J., & Lu, P. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113490 · Cited by 54
MEK Inhibitors Reverse cAMP-Mediated Anxiety in Zebrafish
Lundegaard, P. R., Anastasaki, C., Grant, N. J., Sillito, R. R., Zich, J., Zeng, Z., Paranthaman, K., Larsen, A. P., Armstrong, J. D., Porteous, D. J., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.08.010 · Cited by 45
Person, R. J., Ngalame, N. N. O., Makia, N. L., Bell, M. W., Waalkes, M. P., & Tokar, E. J. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.03.014 · Cited by 51
Activation loop phosphorylation regulates B‐Raf in vivo and transformation by B‐Raf mutants
Köhler, M., Röring, M., Schorch, B., Heilmann, K., Stickel, N., Fiala, G. J., Schmitt, L. C., Braun, S. L., Ehrenfeld, S., Uhl, F. M., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201592097 · Cited by 45
Functional importance of lysyl oxidase family propeptide regions
Trackman, P. C. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0424-4 · Cited by 45
Wagner, S., Vlachogiannis, G., Brandon, A. D. H., Valenti, M. R., Box, G., Jenkins, L., Mancusi, C., Self, A. J., Manodoro, F., Assiotis, I., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0554-z · Cited by 47
Tian, X., Liu, K., Zu, X., Ma, F., Li, Z., Lee, M., Chen, H., Li, Y., Zhao, Y., Liu, F., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.031 · Cited by 44
Smorodinsky-Atias, K., Soudah, N., & Engelberg, D. (2020) · Cells · doi:10.3390/cells9010129 · Cited by 47
Cui, N., Li, L., Feng, Q., Ma, H., Lei, D., & Zheng, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581208 · Cited by 45
Investigating the NRAS 5' UTR as a Target for Small Molecules
Balaratnam, S., Torrey, Z. R., Calabrese, D. R., Banco, M. T., Yazdani, K., Xiao, L., Fullenkamp, C. R., Seshadri, S., Holewinski, R. J., Andrésson, Þ., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2023.05.004 · Cited by 44
Kahraman, A., Karakulak, T., Szklarczyk, D., & von Mering, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-71221-5 · Cited by 44
Kosnopfel, C., Sinnberg, T. W., Sauer, B., Niessner, H., Schmitt, A., Makino, E., Forschner, A., Hailfinger, S., Garbe, C., & Schittek, B. (2017) · Oncotarget · doi:10.18632/oncotarget.16204 · Cited by 43
Tian, X., Cai, J., Ma, S., Fang, Y., Huang, H., Lin, T., Rao, H., Li, M., Xia, Z., Kang, T., et al. (2020) · 癌症:英文版 · doi:10.1002/cac2.12039 · Cited by 44
Ferroptosis, autophagy, tumor and immunity
Xie, Y., Zhou, Y., Wang, J., Lijuan, D., Ren, Y., & Liu, F. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19799 · Cited by 44
Chorzalska, A. D., Ahsan, N., Rao, R. S. P., Roder, K., Yu, X., Morgan, J. W., Tepper, A., Hines, S., Zhang, P., Treaba, D. O., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12186 · Cited by 39
Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer
Clarke, P. A., Roe, T., Swabey, K., Hobbs, S., McAndrew, C., Tomlin, K., Westwood, I. M., Burke, R., van Montfort, R., & Workman, P. (2019) · Oncogene · doi:10.1038/s41388-019-0780-z · Cited by 46
Röck, R., Mayrhofer, J. E., Torres‐Quesada, O., Enzler, F., Raffeiner, A., Raffeiner, P., Feichtner, A., Huber, R. G., Koide, S., Taylor, S. S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav8463 · Cited by 40
Cotzomi-Ortega, I., Rosas-Cruz, A., Ramírez-Ramírez, D., Reyes‐Leyva, J., Rodríguez‐Sosa, M., Aguilar‐Alonso, P., & Maycotte, P. (2020) · Biology · doi:10.3390/biology9010020 · Cited by 44
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
Yuan, X., Tang, Z., Du, R., Yao, Z., Cheung, S., Zhang, X., Wei, J., Zhao, Y., Du, Y., Liu, Y., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12698 · Cited by 39
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Singh, K., Lin, J., Lecomte, N., Mohan, P., Gokce, A., Sanghvi, V. R., Jiang, M., Grbovic-Huezo, O., Burčul, A., Stark, S. G., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2929 · Cited by 39
Ruiz-Pérez, M. V., Sainero‐Alcolado, L., Oliynyk, G., Matuschek, I., Balboni, N., Ubhayasekera, S. J. K. A., Snaebjornsson, M. T., Makowski, K., Aaltonen, K. E., Bexell, D., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102128 · Cited by 38
praja2 regulates KSR1 stability and mitogenic signaling
Rinaldi, L., Donne, R. D., Sepe, M., Porpora, M., Garbi, C., Chiuso, F., Gallo, A., Parisi, S., Russo, L., Bachmann, V. A., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.109 · Cited by 52
MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer
Stefan, E., & Bister, K. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_4 · Cited by 44
PP6 Disruption Synergizes with Oncogenic Ras to Promote JNK-Dependent Tumor Growth and Invasion
Ma, X., Lu, J., Dong, Y., Li, D., Malagón, J. N., & Xu, T. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.092 · Cited by 40
Tai, Y., Zhang, L.-H., Gao, J.-H., Zhao, C., Tong, H., Cheng, Y., Huang, Z.-Y., Liu, R. R., & Tang, C.-W. (2019) · Cancer Management and Research · doi:10.2147/cmar.s183376 · Cited by 42
PYCR, a key enzyme in proline metabolism, functions in tumorigenesis
Li, Y., Bie, J., Song, C., Liu, M., & Luo, J. (2021) · Amino Acids · doi:10.1007/s00726-021-03047-y · Cited by 41
A-Raf: A new star of the family of raf kinases
An, S., Yang, Y., Ward, R. J., Liu, Y., Guo, X., & Xu, T. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1102858 · Cited by 53
Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors
Lechtenberg, B. C., Mace, P. D., Sessions, E. H., Williamson, R., Stalder, R., Wallez, Y., Roth, G. P., Riedl, S. J., & Pasquale, E. B. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00127 · Cited by 37
Zhou, J., Zhao, T., Ma, L., Liang, M., Guo, Y., & Zhao, L. (2017) · Oncotarget · doi:10.18632/oncotarget.21704 · Cited by 38
Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Khaliq, M., & Fallahi‐Sichani, M. (2019) · Cancers · doi:10.3390/cancers11101480 · Cited by 43
Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma
Zheng, Z.-Y., Chu, M.-Y., Lin, W., Zheng, Y.-Q., Xu, X., Chen, Y., Liao, L., Wu, Z., Wang, S., Li, E., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04941-3 · Cited by 40
Liu, C., Wang, S., Zhu, S., Wang, H., Gu, J., Gui, Z., Jin, J., Hou, X.-F., & Shao, Y. (2016) · SpringerPlus · doi:10.1186/s40064-015-1597-z · Cited by 38
ZC3HAV1 promotes the proliferation and metastasis via regulating KRAS in pancreatic cancer
Huang, W., Hua, H., Xiao, G., Yang, X., Yang, Q., & Jin, L. (2021) · Aging · doi:10.18632/aging.203296 · Cited by 39
Single-cell transcriptional atlas of tumor-associated macrophages in breast cancer
Zhang, Y., Zhong, F., & Liu, L. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01887-6 · Cited by 45
Xu, G., Zhang, Q., Cheng, R., Qu, J., & Li, W. (2025) · Autophagy · doi:10.1080/15548627.2025.2452149 · Cited by 50
Ouyang, Q., Zhang, L., Jiang, Y., Ni, X., Chen, S., YE, F., Du, Y., Huang, L., Ding, P., Wang, N., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3408 · Cited by 37
Metadata
- Authors
- Samatar, A. A., & Poulikakos, P. I.
- Affiliations
- Tisch Cancer Institute (US)
- Corresponding author
- Poulikakos, Poulikos I.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-12
- Volume
- 13
- Issue
- 12
- Pages
- 928-942
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2050573392
- Cited by
- 1,163
- References
- 139
- Citations by year
- 2026: 47 · 2025: 77 · 2024: 106 · 2023: 100 · 2022: 102 · 2021: 134 · 2020: 119 · 2019: 105 · 2018: 117 · 2017: 101 · 2016: 108 · 2015: 45 · 2014: 2
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- RAF inhibitors, MEK inhibitors, ERK inhibitor, KRAS mutation, NRAS mutation, BRAF mutation, acquired drug resistance, intrinsic drug resistance, metastatic melanoma, targeted cancer therapy, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.